A higher JCAHO accreditation level did not necessarily guarantee higher-quality care or better outcomes in the management of AMI.
T h e j o i n t c o m m i s s i o n on Accreditation of Healthcare Organizations (JCAHO) is an independent, not-for-profit organization that is the nation's leading accreditor of hospitals. 1 Obtaining JCAHO accreditation is important for hospitals, as the Medicare Act of 1965 decreed that accredited hospitals were deemed to have satisfied federal health and safety requirements necessary to participate in Medicare. 2 Hospitals also have considerable incentive to become accredited for marketing purposes, often using JCAHO accreditation as a "thirdparty endorsement of quality." 3 As a result, approximately 80 percent of the 6,000 U.S. hospitals have sought JCAHO accreditation. 4 JCAHO accreditation is awarded on the basis of a hospital's compliance with a set of standards, which surveyors use in assessing performance during hospital site visits. 5 Standards are assessed in patient assessment and care, patients' rights, clinical ethics, organizational leadership, human resources management, and information management. 6 JCAHO's philosophy is that "if hospitals complied with
Study Methods
n JCAHO accreditation. A hospital seeking to obtain JCAHO accreditation is visited every three years by a survey team that observes hospital operations, conducts interviews, and reviews medical documentation for compliance with a set of standards in forty-five performance areas. 9 JCAHO surveyors assign a score in each performance area and determine an "accreditation level" based on a hospital's overall score and whether JCAHO cited specific areas for improvement (for example, type I recommendations, which indicate the need to resolve unsatisfactory compliance). JCAHO accreditation levels during our study period were (in descending order of compliance) accreditation with commendation, accreditation without (type I) recommendations (hereafter referred to as "accreditation"), accreditation with (type I) recommendations, conditional accreditation, and not accredited. We obtained data from JCAHO on hospital accreditation level and summary scores for hospitals surveyed between 1994 and 1998. Hospitals that had neither a summary score nor an accreditation level reported were considered to be not surveyed.
n Cooperative Cardiovascular Project. The CCP sample included 234,769 feefor-service (FFS) Medicare hospitalizations from acute care, nongovernmental hospitals with a principal discharge diagnosis of AMI, excluding readmissions for AMI, between January 1994 and February 1996 in all fifty states and the District of Columbia. 10 Medical records of sampled patients were abstracted for patients' clinical characteristics, in-hospital treatments, and vital status.
Our study consisted of CCP patients age sixty-five and older who were hospitalized with clinically confirmed AMI. We excluded patients who did not have confirmed AMI (n = 31,186), were younger than age sixty-five (17,593), were readmitted for AMI (25,185), were admitted by interhospital transfer (42,277), had a terminal illness or metastatic cancer (4, 616) , were hospitalized outside the United States (1,760), had unverified mortality (357), and were admitted to hospitals for which American Hospital Association (AHA) data were unavailable (2,363). We also excluded patients admitted to hospitals surveyed by JCAHO for which data were not available (14, 598) . In total, the study cohort comprised 134,579 patients.
n Quality of AMI care and outcomes. Quality of care for AMI was assessed using a set of clinical performance measures from the Centers for Medicare and Medicaid Services (CMS) that assess the use of therapies among patients (ideal candidates) who would benefit from and did not have contraindications for particular treatments. We evaluated the following quality performance measures: use of aspirin or beta-blockers within forty-eight hours of admission, aspirin or beta-blockers anytime during hospitalization, and acute reperfusion therapy (thrombolytic agents or primary angioplasty) within six hours of admission. 11 We examined patient outcomes using thirty-day mortality because the benefits of high-quality hospital care should be evident within this period. Dates of death were obtained from the Medicare Enrollment Database and the Social Security Administration's Master Beneficiary Record.
n Statistical analysis. Chi-square tests and analyses of variance were used to compare differences across hospitals, and the Cochrane-Armitage test was used to evaluate for linear trends in therapy or mortality rates associated with higher accreditation ranking. We compared hospitals' risk-standardized thirty-day mortality rates using the Medicare Mortality Predictor System (MMPS), a disease-specific mortality prediction model for elderly patients. 12 Using logistic regression, we calculated a risk-standardized mortality rate that estimated thirty-day mortality for hospitals in each JCAHO accreditation group, assuming that they had the same patient characteristics as the overall sample. Because of the correlation between hospital characteristics, physician characteristics, and JCAHO accreditation, the primary analyses were risk-adjusted for patient characteristics only; secondary analyses that added adjustment for hospital and physician characteristics were also performed.
To assess the heterogeneity of hospitals' performance within JCAHO accreditation categories, we calculated the observed use of AMI therapies in ideal patients and risk-standardized thirty-day mortality for individual hospitals. Standard deviations and twenty-fifth through seventy-fifth percentiles were evaluated to determine variations within categories in AMI therapy use and thirty-day mortality rates within a particular JCAHO accreditation group. To ensure stability in these estimates, we restricted our analyses to hospitals with at least twenty-five observations. Statistical calculations were performed using STATA 7.0.
Study Results
The final study cohort consisted of 134,579 patients treated at 4,221 hospitals. Approximately one-quarter of hospitals in the study sample were not surveyed by JCAHO (Exhibit 1). Most of the surveyed hospitals received accreditation with recommendations. Nonsurveyed hospitals were more likely than surveyed hospi-tals were to be smaller-volume centers, nonteaching hospitals, publicly owned, and located in a rural setting, and most lacked on-site facilities for cardiac procedures. Surveyed hospitals with higher accreditation levels tended to be largervolume teaching centers and to be located in urban settings with on-site facilities for cardiac procedures (Exhibit 1).
On average, patients in our cohort were elderly (mean age, seventy-six years) and predominantly white (90.9 percent). Although several patient characteristics differed across JCAHO accreditation levels, the magnitude of these differences was small (Exhibit 2). Nonsurveyed hospitals are excluded from tests of global differences and trend. P is less than .001 for differences between surveyed and nonsurveyed hospitals for all characteristics. P values for differences among surveyed hospitals as a group for characteristics were less than .01 in all cases except residency-affiliated (.039) and catheterization or PTCA without bypass (.011). P values for linear trend as accreditation increases were less than .01 for all characteristics except residency-affiliated (.031).
n AMI therapy use. The proportion of patients who were classified as ideal candidates for AMI therapy was generally similar across JCAHO hospital accreditation levels and between surveyed and nonsurveyed hospitals (Exhibit 3). Patients admitted to nonsurveyed hospitals were less likely to receive aspirin and beta-blockers, both on admission and during hospitalization, as well as acute reperfusion therapy, than were patients treated at surveyed hospitals. Among surveyed hospitals, the use of aspirin on admission was highest in hospitals accredited with recommendations and lowest in hospitals with conditional accreditation (Exhibit 3). Aspirin use at any time during hospitalization was similar across accreditation categories. Patients admitted to hospitals accredited with commendation had the highest use of betablockers on admission and at any time during hospitalization, while patients admitted to hospitals with conditional accreditation had the lowest use. Acute reperfusion therapy rates were lowest among patients admitted to conditionally accredited hospitals. These findings were consistent in secondary analyses that adjusted for hospital and physician characteristics. Exhibit 4 illustrates the wide heterogeneity in performance within each JCAHO accreditation level. There was considerable overlap in the proportion of patients receiving aspirin or beta-blockers by hospital accreditation categories. The extensive overlap demonstrates that many hospitals accredited with com- mendation had rates of aspirin and beta-blocker use that were comparable to, and in some cases lower than, those of hospitals that had received conditional accreditation or nonsurveyed hospitals, and vice versa. n Mortality. Hospitals accredited with commendation had lower thirty-day mortality rates than the overall risk-standardized rate; nonsurveyed hospitals had rates that were higher (Exhibit 3). Compared with hospitals accredited with commendation, thirty-day mortality was higher on average for accredited hospitals (hazard ratio [HR] 1.15, p = .01) and hospitals accredited with recommendations (HR 1.06, p < .01). There was a trend toward higher mortality among conditionally accredited hospitals (HR 1.11, p = .39). Further adjustment for hospital and physician characteristics attenuated the relative hazard rates, but the results were consistent with those from the primary analysis (accredited hospitals HR 1.11, p = .05; accredited with recommendations HR 1.05, p = .02; conditional accreditation HR 1.03, p = 0.80; accredited with commendation HR 1.00 [referent]).
Nonsurveyed hospitals had higher thirty-day mortality rates than surveyed hospitals had (HR 1.15, p < .001) when patient characteristics were adjusted for. The increased hazard associated with nonsurveyed hospitals was attenuated after adjustment for hospital and physician characteristics, but remained significant (HR 1.08, p < .001).
However, we found considerable variation in risk-standardized thirty-day mortality rates within each accreditation level (Exhibit 4). The interquartile ranges of risk-standardized thirty-day mortality were primarily located between 15 percent and 25 percent across all accreditation levels. 
Discussion
In our study, nonsurveyed hospitals had lower use of AMI therapies and worse thirty-day outcomes than did hospitals surveyed by JCAHO. However, among surveyed hospitals there were only modest differences in the use of AMI therapies, with the greatest variation observed for the use of beta-blockers. Patients admitted to hospitals accredited with commendation had lower thirty-day mortality rates than those of patients admitted to hospitals in lower accreditation levels. However, we observed much variation in quality measures and outcomes within each JCAHO accreditation category across hospitals.
These findings suggest that the JCAHO standards-based accreditation system has only a modest ability to assess quality of AMI clinical care at any particular hospital. Accreditation does provide some information concerning hospitals' quality of care and outcomes in the aggregate. Indeed, knowing that a hospital participated in the JCAHO survey process suggests superior quality and outcomes compared with nonsurveyed hospitals. It is unknown, however, whether the process of undergoing JCAHO accreditation improves quality of care or whether this association reflects self-selection against JCAHO evaluation by more poorly performing hospitals.
In contrast, accreditation levels were of limited value in differentiating quality among surveyed hospitals. Although beta-blocker use was higher across successive accreditation levels, the absolute differences in rates across accreditation groups were small. Furthermore, there was considerable hospital-level variation in the use of aspirin therapy, the use of beta-blocker therapy, and thirty-day mortality rates within all JCAHO accreditation groups. There were hospitals with high and low rates of AMI therapy use and thirty-day outcomes in all JCAHO accreditation categories, even among hospitals with JCAHO conditional accreditation and non-surveyed hospitals. Thus, a higher JCAHO accreditation level was not necessarily a guarantee of higher-quality care or better outcomes in the management of AMI.
To place the mortality difference across accreditation categories in perspective, the relative difference in risk for thirty-day mortality between surveyed and nonsurveyed hospitals was approximately 15 percent. In contrast, an examination of hospital volume and AMI mortality in the CCP data set identified a 17 percent relative risk difference in thirty-day mortality between the smallest and largest hospital volume quartiles. 13 Accreditation's ability to predict short-term mortality after AMI appears comparable to that of hospital volume.
n Reasons for lack of quality differentiation. There are several reasons why standards-based JCAHO accreditation levels may not be able to differentiate hospitals on the basis of quality. First, many of the JCAHO standards do not assess quality in day-to-day patient care activities. For example, a high degree of compliance with administrative or managerial standards is unlikely to have much bearing on whether patients receive aspirin on admission for AMI, yet these areas account for more than half of all points in a JCAHO survey. Identifying hospitals that are well managed, while informative, is likely to be different than identifying hospitals that provide high-quality clinical care.
Second, the wide range of hospital compliance with JCAHO standards within a single accreditation level may dilute any differences in quality. For example, the category of "accredited with type I recommendations" does not distinguish between hospitals with a single recommendation or many. Similarly, hospitals are assigned conditional accreditation whether they received one citation or several.
Third, JCAHO surveyors exhibit discretion when determining how deeply to probe for potential problems during a survey visit.
14 The impact of variation by and between observers and the reliability of the JCAHO accreditation process are unknown. The Joint Commission itself has recognized that levels of accreditation can be subjective. Commenting on the recent removal of the accreditation with commendation rating, JCAHO president Dennis O'Leary stated that "the distinction between those who get commendation and those who fall just short is artificial in many respects." 15 n JCAHO as an accreditor of quality. Given that JCAHO accreditation cannot differentiate hospitals on the basis of clinical performance, the question is whether JCAHO would be an effective force for assessing and improving quality. There would be several potential advantages for having JCAHO evaluate quality in addition to its current standards-based accreditation.
First, JCAHO has the administrative machinery necessary to evaluate hospitals. Thus, there are financial and logistical benefits to having it evaluate both standards and quality. Second, JCAHO accreditation is sought nearly universally; as a result, the effect of codifying quality into accreditation decisions would be readily disseminated across the country. Third, as the nation's most widely accepted accreditor, JCAHO would likely meet with less resistance from hospitals to the inclusion of quality measures as a natural extension of the accreditation process rather than an entirely new review process.
In spite of the advantages, several challenges remain. First, although JCAHO is an independent institution, it has close ties to the industry it oversees. In a recent critique, the Office of Inspector General of the Department of Health and Human Services reported that JCAHO's stance is "moving towards collegiality rather than regulatory," suggesting a lack of impartiality in evaluating hospitals. 16 Similar concerns have been raised by public-interest groups, which note that half of the members of JCAHO's board of commissioners are from within the industry it is supposed to regulate (the American Hospital Association and the American Medical Association). 17 Second, while JCAHO has indicated a willingness to incorporate quality into accreditation decisions, the specific details are lacking. It is less likely that hospitals will feel an incentive to improve quality if their accreditation is not placed at risk. However, critics contend that very few hospitals are denied accreditation. 18 Whether placing accreditation in jeopardy on the basis of quality will lead to quality improvement remains to be seen.
Third, JCAHO's current system for quality measurement is limited. To its credit, JCAHO has recognized that standards and performance measurement are complementary to assessment of hospital care and has embarked upon a program to integrate clinical performance measures into accreditation decisions. 19 In the mid-1990s JCAHO began requiring accredited hospitals to submit performance data through its "Oryx initiative." Hospitals contracted with vendors to collect data and developed automated databases that feed performance measures back to hospitals and JCAHO each quarter.
However, the Oryx methodology raises questions regarding its validity for measuring quality. Hospitals could select any six of more than 2,000 performance measures. This is problematic because of the potential for hospitals to "game the system" by selecting measures at which they already do well. Also, there is wide variation in clinical importance in the performance measures, which range from length-of-stay, mortality or readmission rates, use of procedures such as cesarean section, patient fall rates, or use of restraints. There is no guarantee that a particular hospital-chosen performance measure represents meaningful differences in quality. Finally, hospitals are evaluated against peers, but the comparison groups are different for each vendor's system. The benchmark group could range from hospitals that used the same vendor's measure, or it may include nonvendor data from the CMS or state health departments, all of which limit Oryx's ability to determine national benchmarks for quality.
To mitigate these limitations, JCAHO recently began requiring hospitals to report a set of "core performance measures" from among four medical conditions (AMI, heart failure, community-acquired pneumonia, and pregnancy) with specific definitions for numerators and denominators. 20 The advantages of using these core measures is that the clinical consensus underlying the quality indicators ensures that they can be compared across both hospitals and time. It is too early to tell whether the reporting of these core measures will affect hospital accreditation or lead to improvements in patient care and outcomes.
n Additional elements of success. Besides selecting appropriate performance measures, establishing standardized benchmarks, and codifying the effects of quality on accreditation, we believe that several additional key elements are necessary if accreditation is to have a substantial and lasting public role for monitoring hospital quality.
Publication of quality measures. Public release of comparative hospital data will allow patients and purchasers to make purchasing decisions based on quality. Consumers would "vote with their feet" in selecting health plans incorporating hospitals that emphasize quality. Purchasers could contract for care based on quality and thereby receive greater value for their health care dollars. Moreover, providers could use explicit measures of quality when negotiating contracts, rather than re-lying on subjective measures or purchasers' perceptions of quality.
Rewards for success. Purchasers' decisions to contract on the basis of quality need not be punitive. The Pacific Business Group on Health (PBGH) has negotiated with several health plans in California to place $8 million at risk for meeting performance measures on patient satisfaction, preventive care measures, and cesarean section rates. 21 In addition, the Leapfrog Group has embarked on a program to reward hospitals for meeting requirements for hospital safety, evidence-based hospital referral, and physician staffing in intensive care units. 22 These examples demonstrate that purchasers are amenable to pursuing reimbursement that rewards superior quality.
Influence of government. The federal government is uniquely positioned to motivate changes in JCAHO accreditation because of accreditation's role in securing hospitals' Medicare reimbursement. This criterion could be leveraged to improve the quality of care for the elderly by having Medicare pay more (or less) depending on providers' quality measures for diseases prevalent in the elderly; by providing a highly visible distinction for hospitals that achieve high standards of performance; or even by tying participation in Medicare to minimum quality-of-care standards. O u r s t u dy s u g ge s ts that an exclusively standards-based accreditation is a limited tool for comparing hospital quality of care, because of the considerable heterogeneity of performance within accreditation levels across hospitals; this highlights the need to measure and report quality indicators directly. The integration of standardized quality measures into the next generation of JCAHO accreditation may address this deficiency. Nevertheless, there are major challenges for JCAHO, as it ponders how to integrate quality into its accreditation process.
